Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2002 Sep;94(9):813–819.

Atherosclerotic vascular disease in systemic lupus erythematosus.

Matthew H Liang 1, Lisa A Mandl 1, Karen Costenbader 1, Ervin Fox 1, Elizabeth Karlson 1
PMCID: PMC2594151  PMID: 12392045

Abstract

In the United States, systemic lupus erythematosus (SLE) disproportionately affects African Americans. It has become a chronic disease with long-term morbidity including chronic renal disease, osteoporosis, cataracts, psychosocial impairment, and importantly, atherosclerotic vascular disease (ASVD). The latter (myocardial infarction, angina, peripheral vascular disease and stroke) are strikingly accelerated, occurring in subjects who are predominantly premenopausal women at an age when ASVD is rare or unusual. Although much is known about the biology, risk factors, and the prevention of atherosclerosis in normal individuals, little work has been done in SLE. In fact, ASVD in people with SLE may be a different disease. Approximately 1.5% of SLE patients per year will have a myocardial infarction or equivalent; about 0.5% of SLE patients per year will have a stroke. The risk factors for ASVD in SLE are based on small, retrospective, single center studies. These suggest that the risk factors known for the general population (i.e., smoking, obesity, sedentary lifestyle, high LDL cholesterol, etc.) are also observed in SLE. The best study of risk factors shows that even accounting for the known factors, SLE and/or its treatment (glucocorticoids) is by far the most important. Our current management of cardiovascular risk factors in SLE patients with ASVD is substandard and our adherence to national guidelines for prevention is substandard. It is not known whether improving either will prevent these disastrous outcomes. Very little is known about the risk factors in African Americans with SLE, although there is data to suggest that they may not be identical to those seen in Caucasian populations. The study of the best and most effective means to prevent ASVD in SLE and in African Americans with SLE and in African Americans with SLE should be a major priority.

Full text

PDF
813

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ames P. R. Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: a unifying 'membrane stress syndrome' hypothesis. Lupus. 1994 Oct;3(5):371–377. doi: 10.1177/096120339400300503. [DOI] [PubMed] [Google Scholar]
  2. Asher C. R., Topol E. J., Moliterno D. J. Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes. Am Heart J. 1999 Dec;138(6 Pt 1):1073–1081. doi: 10.1016/s0002-8703(99)70072-4. [DOI] [PubMed] [Google Scholar]
  3. Asherson R. A., Khamashta M. A., Baguley E., Oakley C. M., Rowell N. R., Hughes G. R. Myocardial infarction and antiphospholipid antibodies in SLE and related disorders. Q J Med. 1989 Dec;73(272):1103–1115. [PubMed] [Google Scholar]
  4. Avorn J., Monette J., Lacour A., Bohn R. L., Monane M., Mogun H., LeLorier J. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998 May 13;279(18):1458–1462. doi: 10.1001/jama.279.18.1458. [DOI] [PubMed] [Google Scholar]
  5. Berlowitz D. R., Ash A. S., Hickey E. C., Friedman R. H., Glickman M., Kader B., Moskowitz M. A. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998 Dec 31;339(27):1957–1963. doi: 10.1056/NEJM199812313392701. [DOI] [PubMed] [Google Scholar]
  6. Brand K., Banka C. L., Mackman N., Terkeltaub R. A., Fan S. T., Curtiss L. K. Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. Arterioscler Thromb. 1994 May;14(5):790–797. doi: 10.1161/01.atv.14.5.790. [DOI] [PubMed] [Google Scholar]
  7. Dahlen G. H., Guyton J. R., Attar M., Farmer J. A., Kautz J. A., Gotto A. M., Jr Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986 Oct;74(4):758–765. doi: 10.1161/01.cir.74.4.758. [DOI] [PubMed] [Google Scholar]
  8. Esdaile J. M., Abrahamowicz M., Grodzicky T., Li Y., Panaritis C., du Berger R., Côte R., Grover S. A., Fortin P. R., Clarke A. E. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001 Oct;44(10):2331–2337. doi: 10.1002/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  9. Flower R. J., Blackwell G. J. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature. 1979 Mar 29;278(5703):456–459. doi: 10.1038/278456a0. [DOI] [PubMed] [Google Scholar]
  10. Futrell N., Millikan C. Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke. 1989 May;20(5):583–591. doi: 10.1161/01.str.20.5.583. [DOI] [PubMed] [Google Scholar]
  11. Fyfe A. I., Rosenthal A., Gotlieb A. I. Immunosuppressive agents and endothelial repair. Prednisolone delays migration and cytoskeletal rearrangement in wounded porcine aortic monolayers. Arterioscler Thromb Vasc Biol. 1995 Aug;15(8):1166–1171. doi: 10.1161/01.atv.15.8.1166. [DOI] [PubMed] [Google Scholar]
  12. Guyton J. R., Dahlen G. H., Patsch W., Kautz J. A., Gotto A. M., Jr Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis. 1985 May-Jun;5(3):265–272. doi: 10.1161/01.atv.5.3.265. [DOI] [PubMed] [Google Scholar]
  13. Hosenpud J. D., Montanaro A., Hart M. V., Haines J. E., Specht H. D., Bennett R. M., Kloster F. E. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med. 1984 Aug;77(2):286–292. doi: 10.1016/0002-9343(84)90704-6. [DOI] [PubMed] [Google Scholar]
  14. Kabakov A. E., Tertov V. V., Saenko V. A., Poverenny A. M., Orekhov A. N. The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunopathol. 1992 Jun;63(3):214–220. doi: 10.1016/0090-1229(92)90225-d. [DOI] [PubMed] [Google Scholar]
  15. Kaell A. T., Shetty M., Lee B. C., Lockshin M. D. The diversity of neurologic events in systemic lupus erythematosus. Prospective clinical and computed tomographic classification of 82 events in 71 patients. Arch Neurol. 1986 Mar;43(3):273–276. doi: 10.1001/archneur.1986.00520030063016. [DOI] [PubMed] [Google Scholar]
  16. Lawrence R. C., Helmick C. G., Arnett F. C., Deyo R. A., Felson D. T., Giannini E. H., Heyse S. P., Hirsch R., Hochberg M. C., Hunder G. G. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998 May;41(5):778–799. doi: 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  17. Liang M. H., Partridge A. J., Daltroy L. H., Straaton K. V., Galper S. R., Holman H. R. Strategies for reducing excess morbidity and mortality in blacks with systemic lupus erythematosus. Arthritis Rheum. 1991 Sep;34(9):1187–1196. doi: 10.1002/art.1780340918. [DOI] [PubMed] [Google Scholar]
  18. Lopes-Virella M. F., Virella G. Atherosclerosis and autoimmunity. Clin Immunol Immunopathol. 1994 Nov;73(2):155–167. doi: 10.1006/clin.1994.1184. [DOI] [PubMed] [Google Scholar]
  19. Manzi S., Meilahn E. N., Rairie J. E., Conte C. G., Medsger T. A., Jr, Jansen-McWilliams L., D'Agostino R. B., Kuller L. H. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997 Mar 1;145(5):408–415. doi: 10.1093/oxfordjournals.aje.a009122. [DOI] [PubMed] [Google Scholar]
  20. Manzi S., Selzer F., Sutton-Tyrrell K., Fitzgerald S. G., Rairie J. E., Tracy R. P., Kuller L. H. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999 Jan;42(1):51–60. doi: 10.1002/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  21. Metcalf P. A., Sharrett A. R., Folsom A. R., Duncan B. B., Patsch W., Hutchinson R. G., Szklo M., Davis C. E., Tyroler H. A. African American-white differences in lipids, lipoproteins, and apolipoproteins, by educational attainment, among middle-aged adults: the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 1998 Oct 15;148(8):750–760. doi: 10.1093/oxfordjournals.aje.a009696. [DOI] [PubMed] [Google Scholar]
  22. Moliterno D. J., Jokinen E. V., Miserez A. R., Lange R. A., Willard J. E., Boerwinkle E., Hillis L. D., Hobbs H. H. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol. 1995 Jul;15(7):850–855. doi: 10.1161/01.atv.15.7.850. [DOI] [PubMed] [Google Scholar]
  23. Petri M., Lakatta C., Magder L., Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med. 1994 Mar;96(3):254–259. doi: 10.1016/0002-9343(94)90151-1. [DOI] [PubMed] [Google Scholar]
  24. Petri M., Roubenoff R., Dallal G. E., Nadeau M. R., Selhub J., Rosenberg I. H. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996 Oct 26;348(9035):1120–1124. doi: 10.1016/S0140-6736(96)03032-2. [DOI] [PubMed] [Google Scholar]
  25. Petri M., Spence D., Bone L. R., Hochberg M. C. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992 Sep;71(5):291–302. doi: 10.1097/00005792-199209000-00004. [DOI] [PubMed] [Google Scholar]
  26. Ridker P. M., Stampfer M. J., Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001 May 16;285(19):2481–2485. doi: 10.1001/jama.285.19.2481. [DOI] [PubMed] [Google Scholar]
  27. Sandkamp M., Funke H., Schulte H., Köhler E., Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem. 1990 Jan;36(1):20–23. [PubMed] [Google Scholar]
  28. Schwartz S. M., Reidy M. A., O'Brien E. R. Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb Haemost. 1995 Jul;74(1):541–551. [PubMed] [Google Scholar]
  29. Sorrentino M. J., Vielhauer C., Eisenbart J. D., Fless G. M., Scanu A. M., Feldman T. Plasma lipoprotein (a) protein concentration and coronary artery disease in black patients compared with white patients. Am J Med. 1992 Dec;93(6):658–662. doi: 10.1016/0002-9343(92)90199-l. [DOI] [PubMed] [Google Scholar]
  30. Stafford R. S., Blumenthal D., Pasternak R. C. Variations in cholesterol management practices of U.S. physicians. J Am Coll Cardiol. 1997 Jan;29(1):139–146. doi: 10.1016/s0735-1097(96)00441-x. [DOI] [PubMed] [Google Scholar]
  31. Walsh S. J., Algert C., Gregorio D. I., Reisine S. T., Rothfield N. F. Divergent racial trends in mortality from systemic lupus erythematosus. J Rheumatol. 1995 Sep;22(9):1663–1668. [PubMed] [Google Scholar]
  32. West S. G. Neuropsychiatric lupus. Rheum Dis Clin North Am. 1994 Feb;20(1):129–158. [PubMed] [Google Scholar]
  33. Wick G., Schett G., Amberger A., Kleindienst R., Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995 Jan;16(1):27–33. doi: 10.1016/0167-5699(95)80067-0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES